SCHEMBL7023644

SCHEMBL7023644

Cc1cc(C)c(ON)c(C)c1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAPGEF4 Q8WZA2 3/20 0.39
ALDH1A1 P00352 3/20 0.39
KDM4E B2RXH2 2/20 0.39
MAPT P10636 2/20 0.39
LMNA P02545 1/20 0.39
GAA P10253 1/20 0.39
TSHR P16473 1/20 0.38
ACHE P22303 1/20 0.36
SMN1; SMN2 Q16637 2/20 0.35
HSD17B10 Q99714 1/20 0.35
NOS3 P29474 1/20 0.33
NOS1 P29475 1/20 0.33
NOS2 P35228 1/20 0.33
KMT2A Q03164 1/20 0.32
CYP1A2 P05177 1/20 0.32
CYP2A6 P11509 1/20 0.32
GLA P06280 1/20 0.32
F2 P00734 2/20 0.31
PRSS1 P07477 2/20 0.31
PRSS2 P07478 2/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22859953 0.78 IDO1 (0.36) RAPGEF4
Methylamine SCHEMBL18641330 0.77 RAPGEF4 (0.39) RAPGEF4ALDH1A1KDM4EMAPTLMNA
SCHEMBL242786 0.75 RAPGEF4 (0.43) RAPGEF4ALDH1A1KDM4EMAPTLMNA
SCHEMBL11420240 0.75 RAPGEF4 (0.43) RAPGEF4ALDH1A1KDM4EMAPTLMNA
SCHEMBL10798387 0.73 RAPGEF4 (0.41) RAPGEF4ALDH1A1KDM4EMAPTLMNA
SCHEMBL129762 0.73 ACHE (0.57) RAPGEF4ALDH1A1MAPTLMNAACHE
Phosphine SCHEMBL22634061 0.73 RAPGEF4 (0.41) RAPGEF4ALDH1A1KDM4EMAPTLMNA
SCHEMBL1047352 0.71 RAPGEF4 (0.39) RAPGEF4ALDH1A1KDM4EMAPTLMNA
SCHEMBL15364372 0.71 RAPGEF4 (0.39) RAPGEF4ALDH1A1KDM4EMAPTLMNA
SCHEMBL31067297 0.71 RAPGEF4 (0.39) RAPGEF4ALDH1A1KDM4EMAPTLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-118401516-A TYK2 inhibitors, compositions and methods thereof 凌科药业(杭州)有限公司 2024-07-26 CN disclosed
EP-0973395-B1 DIARYL ETHERS AND PROCESSES FOR THEIR PREPARATION AND HERBICIDAL AND DESICCANT COMPOSITIONS CONTAINING THEM ISK AMERICAS INC (US) 2003-12-03 EP disclosed
US-20030032807-A1 Method for the production of 1-amino -3-aryl -uracils BAYER AKTIENGESELLSCHAFT (DE) 2003-02-13 US disclosed
EP-1257540-A1 METHOD FOR THE PRODUCTION OF 1-AMINO-3-ARYL-URACILS Bayer Aktiengesellschaft (DE) 2002-11-20 EP disclosed
US-6479435-B1 OR DIARYL SULFIDES, 1-(4-CHLORO-2-FLUORO-5-(2-PYRIMIDYLOXY)PHENYL)-4-DIFLUOROMETHY L-3-METHYL-1,4-DIHYDRO-1,2,4-TRIAZOLIN-5-ONE FOR EXAMPLE ISK AMERICAS INCORPORATED 2002-11-12 US disclosed
US-20020161224-A1 Diaryl ethers and processes for their preparation and herbicidal and desiccant compositions containing them PULMAN DAVID A (US) 2002-10-31 US disclosed
US-6333296-B1 FOR CONTRILLING WEEDS ISK AMERICAS INCORPORATED 2001-12-25 US disclosed
US-6303543-B1 Diaryl ethers and processes for their preparation and herbicidal and desiccant compositions containing them ISHIHARA SANGYO KAISHA, LTD. (JP) 2001-10-16 US disclosed
EP-0973395-A4 DIARYL ETHERS AND PROCESSES FOR THEIR PREPARATION AND HERBICIDAL AND DESICCANT COMPOSITIONS CONTAINING THEM ISK AMERICAS INC (US) 2001-10-04 EP disclosed
WO-2001058883-A1 METHOD FOR THE PRODUCTION OF 1-AMINO-3-ARYL-URACILS BAYER AKTIENGESELLSCHAFT (DE) 2001-08-16 WO disclosed
US-6121201-A HETEROARYL SUBSTITUTED HALO-PYRAZOLE SUBSTITUTED DIARYL ETHERS OR THIOETHERS ISHIHARA SANGYO KAISHA, LTD. (JP) 2000-09-19 US disclosed
EP-0973395-A1 DIARYL ETHERS AND PROCESSES FOR THEIR PREPARATION AND HERBICIDAL AND DESICCANT COMPOSITIONS CONTAINING THEM ISK Americas Incorporated (US) 2000-01-26 EP disclosed
WO-1998041093-A1 DIARYL ETHERS AND PROCESSES FOR THEIR PREPARATION AND HERBICIDAL AND DESICCANT COMPOSITIONS CONTAINING THEM ISK AMERICAS INCORPORATED (US) 1998-09-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030032807-A1 Method for the production of 1-amino -3-aryl -uracils NQO2, QARS1, NUDT1 RAPGEF4 3622/4885ALDH1A1 871/4885KDM4E 1479/4885
US-20020161224-A1 Diaryl ethers and processes for their preparation and herbicidal and desiccant compositions containing them HDHD5, DDT, CBR3 RAPGEF4 4089/4885ALDH1A1 236/4885KDM4E 757/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.